Burgeoning Rise in Cancer Incidence: Driving Generics Market

Around 12.7 Million new cases are expected to further drive the cost associated with cancer, compelling the government to promote generics in order to drive costs down.


Noida, UP -- (SBWIRE) -- 01/20/2014 -- Globally, around 12.7 Million new cancer cases were estimated in 2012. During the last decade, the global burden of cancer has significantly expanded with the incidence of new cancer cases and deaths. In such a scenario, the cost associated with cancer has also gone up. As a result, governments across the seven major pharmaceutical markets have started to prioritize their cost containment policies in order to drive costs down. Strategies are now being implemented to approve the sale of generic drugs across various nations.

According to our report titled, “Cancer Generics Market Outlook 2017”, the global cancer generics market is expected to reach US$ 19 Billion by 2017 as a result of the cost containment policies of the government. This growth can also be attributed to a lot of branded cancer drugs whose patents are expected to expire within the next 5 years. This will provide a major thrust to the generics which are comparatively cheaper than their branded counterparts. Generic manufacturers can cash in on this opportunity to increase their market revenue and global presence.

The report provides an insight to the various parameters associated with Cancer Generics. It focuses on the trends and drivers that would be instrumental in shaping the market, evaluating the role and impact of each driver. Also covered is the segmentation of the generics market by disease types, with emphasis on current and future incidence, regional analysis and the various generic treatment options available.

The thorough study asserts that Cancer Generics in developing countries is going to be the focus area for majority of players with enormous growth potential in the near future.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM613.htm

Some of our Related Reports are:

- Cancer Generics Market Analysis (http://www.rncos.com/Report/IM353.htm)
- Japan Generics Market Analysis (http://www.rncos.com/Report/IM371.htm)
- Generic Drug Market in Canada (http://www.rncos.com/Report/IM598.htm)
- Booming Generics Drug Market in India (http://www.rncos.com/Report/IM256.htm)
- UK Generics Market Analysis (http://www.rncos.com/Report/IM313.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.